IPP Bureau
Lupin launches Mirabegron Extended-Release Tablets in US
By IPP Bureau - April 22, 2024
Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of US$ 1,019 million in the US
Biocon receives approval from SAHPRA for Tacrolimus Capsule
By IPP Bureau - April 22, 2024
Tacrolimus is an immunosuppressant used in the treatment of organ transplant patients
Sentynl Therapeutics receives marketing authorization for Nulibry from UK MHRA
By IPP Bureau - April 22, 2024
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Evotech and Variant Bio partner to develop fibrosis treatment
By IPP Bureau - April 22, 2024
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
Boehringer Ingelheim introduces NexGard Spectra for dogs in India
By IPP Bureau - April 22, 2024
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
By IPP Bureau - April 22, 2024
The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
Zydus launches Mirabegron ER Tablets in the US
By IPP Bureau - April 22, 2024
Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market
Akums launches Bharosa campaign
By IPP Bureau - April 22, 2024
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
.png "Mac-Chem Products (India)’s Boisar facility renews EU-GMP certification")
Mac-Chem Products (India)’s Boisar facility renews EU-GMP certification
By IPP Bureau - April 22, 2024
Roche gets FDA approval for Alecensa in early lung cancer
By IPP Bureau - April 22, 2024
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
Vertex announces advancements of Suzetrigine in acute and neuropathic pain
By IPP Bureau - April 22, 2024
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Jubilant Pharmova to close manufacturing operations of Solid dosage formulation facility of Jubilant Cadista USA
By IPP Bureau - April 19, 2024
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
Shilpa Medicare launches Pemetrexed injection
By IPP Bureau - April 19, 2024
Pemetrexed Injection is used as a drug, in the treatment of non-small cell lung cancer in combination with other chemotherapy agents
Fresenius Kabi USA flies complaint against NATCO Pharma
By IPP Bureau - April 19, 2024
Natco Pharma intends to defend the matter accordingly
